Literature DB >> 26435191

Functional roles of enhancer of zeste homolog 2 in gliomas.

Yatao Yin1, Shuwei Qiu1, Ying Peng2.   

Abstract

Gliomas are the most common and lethal type of primary malignant brain tumor. Due to the infiltrative nature and high resistance to standard first line treatment with combinations of radiation and chemotherapy, the prognosis of patient is very poor. Recently, accumulated evidence suggests that enhancer of zeste homolog 2 (EZH2) serves as an oncogene and is involved in multiple glioma cell processes, including cell cycle, invasion, glioma stem cell maintenance, drug and radiotherapy resistance and so on. In this review, we will focus on updating current knowledge of EZH2 in gliomas. Moreover, the regulation of EZH2 by microRNAs and long non-coding RNAs and the therapeutic strategies targeting EZH2 for gliomas will also be discussed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EZH2; Glioblastoma; Glioma stem cells; Long non-coding RNAs; MicroRNAs

Mesh:

Substances:

Year:  2015        PMID: 26435191     DOI: 10.1016/j.gene.2015.09.080

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  13 in total

1.  Citrullination/Methylation Crosstalk on Histone H3 Regulates ER-Target Gene Transcription.

Authors:  Kathleen W Clancy; Anna-Maria Russell; Venkataraman Subramanian; Hannah Nguyen; Yuewei Qian; Robert M Campbell; Paul R Thompson
Journal:  ACS Chem Biol       Date:  2017-05-09       Impact factor: 5.100

Review 2.  The protean world of non-coding RNAs in glioblastoma.

Authors:  Ramasamy Paulmurugan; Meenakshi Malhotra; Tarik F Massoud
Journal:  J Mol Med (Berl)       Date:  2019-05-25       Impact factor: 4.599

3.  The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells.

Authors:  Tianfu Yu; Yingyi Wang; Qi Hu; WeiNing Wu; Youzhi Wu; Wenjin Wei; Dongfeng Han; Yongping You; Ning Lin; Ning Liu
Journal:  Oncotarget       Date:  2017-09-27

4.  EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment.

Authors:  Yatao Yin; Shuwei Qiu; Xiangpen Li; Bo Huang; Yun Xu; Ying Peng
Journal:  J Neuroinflammation       Date:  2017-11-13       Impact factor: 8.322

Review 5.  An Insight into the Increasing Role of LncRNAs in the Pathogenesis of Gliomas.

Authors:  Yuanliang Yan; Zhijie Xu; Zhi Li; Lunquan Sun; Zhicheng Gong
Journal:  Front Mol Neurosci       Date:  2017-02-28       Impact factor: 5.639

Review 6.  MicroRNA in Glioblastoma: An Overview.

Authors:  Barbara Banelli; Alessandra Forlani; Giorgio Allemanni; Anna Morabito; Maria Pia Pistillo; Massimo Romani
Journal:  Int J Genomics       Date:  2017-11-06       Impact factor: 2.326

7.  Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1.

Authors:  Wenzheng Luo; Xueyuan Li; Zhenyu Song; Xuqiang Zhu; Shanshan Zhao
Journal:  Aging (Albany NY)       Date:  2019-06-11       Impact factor: 5.682

Review 8.  Metabolism and Autoimmune Responses: The microRNA Connection.

Authors:  Alessandra Colamatteo; Teresa Micillo; Sara Bruzzaniti; Clorinda Fusco; Silvia Garavelli; Veronica De Rosa; Mario Galgani; Maria Immacolata Spagnuolo; Francesca Di Rella; Annibale A Puca; Paola de Candia; Giuseppe Matarese
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

9.  Targetome Analysis Revealed Involvement of MiR-126 in Neurotrophin Signaling Pathway: A Possible Role in Prevention of Glioma Development.

Authors:  Maedeh Rouigari; Moein Dehbashi; Kamran Ghaedi; Meraj Pourhossein
Journal:  Cell J       Date:  2018-03-18       Impact factor: 2.479

10.  Dissecting the role of novel EZH2 inhibitors in primary glioblastoma cell cultures: effects on proliferation, epithelial-mesenchymal transition, migration, and on the pro-inflammatory phenotype.

Authors:  Giulia Stazi; Ludovica Taglieri; Alice Nicolai; Annalisa Romanelli; Rossella Fioravanti; Stefania Morrone; Manuela Sabatino; Rino Ragno; Samanta Taurone; Marcella Nebbioso; Raffaella Carletti; Marco Artico; Sergio Valente; Susanna Scarpa; Antonello Mai
Journal:  Clin Epigenetics       Date:  2019-12-02       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.